Fresenius SE & Co. KGaA · XETR:FRE
Fresenius SE & Co. KGaA — Q2 2015 Earnings Presentation
29 slides from Fresenius SE & Co. KGaA's earnings presentation, Jul 30, 2015
Slide 1: Conference Call – Q2/2015 Results
Conference Call – Q2/2015 Results July 30, 2015
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive
Slide 3: Fresenius Group: Financial Results
Fresenius Group: Financial Results Q2/15 H1/15 Sales €6,946 m €13,429 m Growth cc 13% 13% Growth actual rates 26% 25% EBIT1 €971 m €1,822 m Growth cc 12% 15% Growth actual rates 28% 30% Net income1 €350 m €642 m Growth cc 22% 19% Growth actual rates 35% 32% 1 Before special items For a detailed over
Slide 4: Fresenius Group: Financial Results by Business Segment
Fresenius Group: Financial Results by Business Segment Growth Growth Q2/15 Q2 YoY H1/15 H1 YoY Sales US$4,199 m 9% US$8,159 m 10% EBIT US$547 m -2% US$1,051 m 5% Sales €1,538 m 23% €2,932 m 19% EBIT1 €314 m 50% €571 m 39% Sales €1,383 m 7% €2,774 m 10% EBIT1 €160 m 18% €307 m 23% Sales €255 m 23% €4
Slide 5: Q2 Business Segment Update
Q2 Business Segment Update Accelerated sales and EBIT growth Regional development North America - IV drug shortages persisting - 5 product launches YTD - Expected 2015 organic sales growth range now 8% to 12% Europe - Continued strong business momentum with 5% organic sales growth - Timing of contra
Slide 6: Q2 Business Segment Update
Q2 Business Segment Update Hospital business fully on track - 100 bps sequential margin expansion reflects continued successful integration of acquired Rhön hospitals - Fully on track to meet full-year guidance Strong organic sales growth - Project business drives organic sales growth (31% organic s
Slide 7: Group Financials Q2/15 − Outlook 2015
Group Financials Q2/15 − Outlook 2015 Conference Call – Q2/15 Results, Fresenius SE & Co. KGaA, Investor Relations © Copyright, July 30, 2015 Page 7
Slide 8: Fresenius Group: Profit and Loss Statement
Fresenius Group: Profit and Loss Statement Growth Q2 YoY Growth H1 YoY €m Q2/15 actual constant H1/15 actual constant rates rates rates rates Sales 6,946 26% 13% 13,429 25% 13% EBIT1 971 28% 12% 1,822 30% 15% Net interest -165 -14% -1% -330 -17% -4% Income taxes1 -234 -18% -2% -441 -33% -16% Net inc
Slide 9: Fresenius Kabi: Strong EBIT Growth
Fresenius Kabi: Strong EBIT Growth Growth Growth €m Q2/15 H1/15 Q2 YoY H1 YoY Europe 91 12% 174 16% Margin 17.0% 150 bps 16.5% 190 bps North America 227 63% 403 41% Margin 41.0% 290 bps 39.3% 100 bps Asia-Pacific/Latin America/Africa 70 19% 133 23% Margin 15.5% -70 bps 15.6% 10 bps Corporate and Cor
Slide 10: Fresenius Helios: Strong EBIT margin increase
Fresenius Helios: Strong EBIT margin increase Growth Growth €m Q2/15 H1/15 Q2 YoY H1 YoY Total sales 1,383 7% 2,774 10% EBIT Established clinic portfolio 155 15% 298 20% Margin 11.7% 120 bps 11.5% 160 bps Acquisitions 5 9 (consolidation <1 yr) 7.9% 4.7% Margin Total EBIT 160 18% 307 23% Margin 11.6%
Slide 11: Cash Flow Development
Cash Flow Development €m Operating CF Capex (net) Free Cash Flow1 Q2/15 LTM Margin Q2/15 LTM Margin Q2/15 LTM Margin 271 13.9% -79 -6.3% 192 7.6% 3 117 10.6% -51 -4.7% 66 5.9% -7 0.8% -6 -1.1% -13 -0.3% Corporate/ Other -10 n.a. -2 n.a. -12 n.a. 2 2 excl. FMC 371 11.7% -138 -5.2% 233 6.5% Group 720
Slide 12: Fresenius Group: Increased Outlook for Fresenius Kabi
Fresenius Group: Increased Outlook for Fresenius Kabi Old New Fresenius Sales growth organic 4% – 7% 6% – 8% Kabi EBIT growth constant currency 11% – 14% 18% – 21% Fresenius Sales growth organic 3% – 5% Helios Sales growth reported 6% – 9% EBIT €630 – 650 m Fresenius Sales growth organic single–digi
Slide 13: Fresenius Group: Increased Earnings Guidance
Fresenius Group: Increased Earnings Guidance Old New Revenue growth 7% ‒ 10% 8% ‒ 10% at constant currency Net income growth1 13% – 16% 18% – 21% at constant currency 1 Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2015 before integration costs for hospitals of Rhön-Klinikum AG
Slide 14: Attachments
Attachments Conference Call – Q2/15 Results, Fresenius SE & Co. KGaA, Investor Relations © Copyright, July 30, 2015 Page 14
Slide 15: Fresenius Group: Overview – Calculation of Noncontrolling Interest
Fresenius Group: Overview – Calculation of Noncontrolling Interest €m H1/15 FY/14 Earnings before tax and noncontrolling interest 1,478 2,512 Taxes -427 -700 Noncontrolling interest, thereof -409 -745 Fresenius Medical Care net income not -279 -542 attributable to Fresenius (Q2/15: ~69%) Noncontroll
Slide 16: Fresenius Group: Cash Flow
Fresenius Group: Cash Flow LTM LTM Growth €m Q2/15 Q2/14 Margin Margin YoY Operating Cash Flow 720 11.9% 610 10.1% 18% Capex (net) -332 -5.4% -289 -5.5% -15% Free Cash Flow 388 6.5% 321 4.6% 21% (before acquisitions and dividends) Acquisitions (net) -61 -161 62% Dividends -476 -429 -11% Free Cash Fl
Slide 17: Cash Flow Development LTM
Cash Flow Development LTM €m Operating CF Capex (net) Free Cash Flow1 LTM H1/15 LTM Margin LTM H1/15 LTM H1/15 LTM H1/15 LTM Margin 780 13.9% -354 -6.3% 426 7.6% 584 10.6% -261 -4.7% 323 5.9%3 9 0.8% -12 -1.1% -3 -0.3% Corporate/ Other -24 n.a. -11 n.a. -35 n.a. excl. FMC 1,349 11.7%2 -638 -5.2% 711
Slide 18: Fresenius Group: Leverage Ratio
Fresenius Group: Leverage Ratio Net debt/EBITDA (at annual average FX rates for both EBITDA and net debt) 4.0 3.5 3.51 3.40 3.32 3.26 3.26 3.07 3.12 3.0 3.07 Target 2015YE: 2.60 2.57 2.72 ~3.0 2.63 2.5 2.0 1 1 1 2 1 1 1 1 1 3 YE/08 YE/09 YE/10 YE/11 YE/12 YE/13 Q1/14 Q2/14 Q3/14 YE/14 Q1/15 Q2/15 YE
Slide 19: Fresenius Kabi: Strong Organic Sales Growth
Fresenius Kabi: Strong Organic Sales Growth Organic Organic €m Q2/15 Growth H1/15 Growth Q2 YoY H1 YoY I.V. Drugs 646 28% 1,191 17% Clinical Nutrition 400 7% 772 8% Infusion Therapy 237 0% 468 0% Medical Devices/ Transfusion Technology 255 -2% 501 -1% Total sales 1,538 11% 2,932 8% Conference Call –
Slide 20: Fresenius Kabi: Strong Organic Sales Growth
Fresenius Kabi: Strong Organic Sales Growth Organic Organic €m Q2/15 Growth H1/15 Growth Q2 YoY H1 YoY Europe 534 5% 1,052 5% North America 553 24% 1,026 13% Asia-Pacific 296 4% 564 4% Latin America/Africa 155 14% 290 11% Total sales 1,538 11% 2,932 8% Conference Call – Q2/15 Results, Fresenius SE &
Slide 21: Fresenius Helios: Sales Growth
Fresenius Helios: Sales Growth Growth Growth €m Q2/15 H1/15 Q2 YoY H1 YoY Established clinic portfolio 1,320 2% 2,583 3% Acquisitions 63 191 (consolidation <1 yr) Total sales 1,383 7% 2,774 10% Conference Call – Q2/15 Results, Fresenius SE & Co. KGaA, Investor Relations © Copyright, July 30, 2015 Pa
Slide 22: Fresenius Helios: Performance Indicators
Fresenius Helios: Performance Indicators H1/15 H1/14 Change No. of hospitals1 111 110 1% - Acute care clinics 87 86 1% - Post-acute care clinics 24 24 0% No. of beds1 34,391 34,188 1% - Acute care clinics 29,218 29,068 1% - Post-acute care clinics 5,173 5,120 1% Admissions - Acute care (inpatient) 5
Slide 23: Fresenius Helios: Sales Influence Hospital Acquisitions / Divestitures
Fresenius Helios: Sales Influence Hospital Acquisitions / Divestitures Acquisitions Annualized sales Hospitals from Rhön-Klinikum ~€1.9 bn ~70% consolidated as of January 1, 2014 ~20% consolidated as of March 1, 2014 HSK consolidated as of June 30, 2014 ~€40 m Cuxhaven consolidated as of August 1, 2
Slide 24: Fresenius Vamed: Strong Sales Growth
Fresenius Vamed: Strong Sales Growth Growth Growth €m Q2/15 H1/15 Q2 YoY H1 YoY Project business 122 31% 202 17% Service business 133 17% 261 16% Total sales 255 23% 463 16% Total EBIT 9 0% 16 7% Margin 3.5% -80 bps 3.5% -30 bps Order intake1 92 -50% 284 -5% Order backlog1 1,479 6%2 1 Project busine
Slide 25: Fresenius Group: Key Figures According to IFRS
Fresenius Group: Key Figures According to IFRS H1/15 H1/15 €m U.S. GAAP IFRS Sales 13,429 13,622 EBIT1 1,822 1,819 Net interest -330 -330 Net income2 642 634 Net income3 642 629 Operating Cash flow 1,251 1,257 Balance sheet total 42,271 42,370 1 Before special items 2 Net income attributable to shar
Slide 26: Reconciliation according to U.S. GAAP – Q2 2015 / Q2 2014
Reconciliation according to U.S. GAAP – Q2 2015 / Q2 2014 The Group’s U.S. GAAP financial results as of June 30, 2015 and June 30, 2014 comprise special items. Net income attributable to shareholders of Fresenius SE & Co. KGaA was adjusted for these special items. The table below shows the special i
Slide 27: Reconciliation according to U.S. GAAP – H1 2015 / H1 2014
Reconciliation according to U.S. GAAP – H1 2015 / H1 2014 The Group’s U.S. GAAP financial results as of June 30, 2015 and June 30, 2014 comprise special items. Net income attributable to shareholders of Fresenius SE & Co. KGaA was adjusted for these special items. The table below shows the special i
Slide 28: Share Information
Share Information Share key facts Number of shares1 543,478,807 WKN / ISIN 578560 / DE0005785604 Ticker symbol FRE Bloomberg symbol FRE GR Reuters symbol FREG.de ADR key facts Ratio 4 ADRs = 1 ordinary share ADR CUSIP / ISIN 35804M105 / US35804M1053 Ticker symbol FSNUY Exchange OTCQX International P
Slide 29: Financial Calendar 2015
Financial Calendar 2015 29.10.2015 Report on 3rd quarter 2015 Please note that these dates could be subject to change. Contact Markus Georgi SVP Investor Relations Leslie Iltgen VP Investor Relations Fresenius SE & Co. KGaA Fresenius SE & Co. KGaA phone: +49 6172 608-2485 phone: +49 6172 608-4478 e-
Fresenius SE & Co. KGaA — Q2 2015 Earnings Presentation on 6ix